{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:00:08Z","timestamp":1777647608750,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>To evaluate the reproducibilities of Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST) for hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE) using contrast-enhanced computed tomography (CT).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective study included 105 consecutive patients with confirmed HCC recruited from November 2002 to June 2012. The study protocol has been pre-registered at (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/osf.io\/nxg4q\/\" ext-link-type=\"uri\">https:\/\/osf.io\/nxg4q\/<\/jats:ext-link>) on the Open Science Framework (OSF) platform. Patients with pre-procedural and follow-up CT scans who had solely received TACE were included. The tumor response evaluation to TACE was conducted using RECIST 1.1 and mRECIST guidelines. Three experienced board-certified abdominal radiologists interpreted CT scans.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>For pre-procedure CT, the agreement was more excellent when using RECIST guidelines with a \u201cmarginally significant\u201d p-value of 0.056. This trend continued for post-procedural CT scans, with RECIST again showing significantly higher agreement with a p-value of 0.001. When evaluating the four categories of response, Gwet\u2019s coefficient was 0.90 (CI\u2009=\u20090.83 to 0.97) for RECIST and 0.80 (CI\u2009=\u20090.63 to 0.90) for mRECIST. Conversely, the Fleiss Kappa analysis demonstrated a higher agreement for the mRECIST guideline. There was an insignificant difference in RECIST and mRECIST guidelines inter-reader agreement when categorizing the tumor response with a p-value of 0.101.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Both guidelines\u2019 inter-reader reproducibility in assessing tumor response through CT after the TACE procedure was excellent, with RECIST\u2019s reproducibility being very slightly better.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12880-025-01688-z","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T13:30:39Z","timestamp":1746279039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Inter-reader agreement of RECIST and mRECIST criteria for assessing response to transarterial chemoembolization in hepatocellular carcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Saeed","family":"Mohammadzadeh","sequence":"first","affiliation":[],"role":[{"role":"author","vocab":"crossref"}]},{"given":"Alisa","family":"Mohebbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocab":"crossref"}]},{"given":"Ali","family":"Abdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocab":"crossref"}]},{"given":"Afshin","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocab":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"issue":"2","key":"1688_CR1","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","volume":"72","author":"AG Singal","year":"2020","unstructured":"Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020;72(2):250\u201361.","journal-title":"J Hepatol"},{"issue":"10","key":"1688_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589\u2013604.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"1688_CR3","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/hep.30161","volume":"69","author":"D Kim","year":"2019","unstructured":"Kim D, Li AA, Perumpail BJ, Gadiparthi C, Kim W, Cholankeril G, et al. Changing trends in Etiology-Based and Ethnicity-Based annual mortality rates of cirrhosis and hepatocellular carcinoma in the united States. Hepatology. 2019;69(3):1064\u201374.","journal-title":"Hepatology"},{"issue":"2","key":"1688_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1053\/j.gastro.2006.05.021","volume":"131","author":"K Takayasu","year":"2006","unstructured":"Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131(2):461\u20139.","journal-title":"Gastroenterology"},{"issue":"8","key":"1688_CR5","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.dld.2015.04.004","volume":"47","author":"BK Kim","year":"2015","unstructured":"Kim BK, Kim KA, Kim MJ, Park JY, Kim DY, Ahn SH, et al. Inter-observer variability of response evaluation criteria for hepatocellular carcinoma treated with chemoembolization. Dig Liver Dis. 2015;47(8):682\u20138.","journal-title":"Dig Liver Dis"},{"issue":"6","key":"1688_CR6","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/hep.24670","volume":"54","author":"J Bruix","year":"2011","unstructured":"Bruix J, Reig M, Rimola J, Forner A, Burrel M, Vilana R, et al. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology. 2011;54(6):2238\u201344.","journal-title":"Hepatology"},{"issue":"12","key":"1688_CR7","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1177\/0284185114560937","volume":"56","author":"D Hyun","year":"2015","unstructured":"Hyun D, Shin SW, Cho SK, Park KB, Park HS, Choo SW, et al. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated Iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. Acta Radiol. 2015;56(12):1437\u201345.","journal-title":"Acta Radiol"},{"issue":"3","key":"1688_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0168-8278(01)00130-1","volume":"35","author":"J Bruix","year":"2001","unstructured":"Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, European Association for the Study of the Liver. Clinical management of hepatocellular carcinoma. J Hepatol. 2001;35(3):421\u201330. Conclusions of the Barcelona-2000 EASL conference.","journal-title":"J Hepatol"},{"key":"1688_CR9","doi-asserted-by":"crossref","unstructured":"Candita G, Rossi S, Cwiklinska K, Fanni SC, Cioni D, Lencioni R et al. Imaging diagnosis of hepatocellular carcinoma: A State-of-the-Art review. Diagnostics (Basel Switzerland). 2023;13(4).","DOI":"10.3390\/diagnostics13040625"},{"issue":"3","key":"1688_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/cncr.24050","volume":"115","author":"A Forner","year":"2009","unstructured":"Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115(3):616\u201323.","journal-title":"Cancer"},{"issue":"2","key":"1688_CR11","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1148\/radiol.2502072222","volume":"250","author":"IR Kamel","year":"2009","unstructured":"Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009;250(2):466\u201373.","journal-title":"Radiology"},{"issue":"2","key":"1688_CR12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00330-014-3412-6","volume":"25","author":"CP Corona-Villalobos","year":"2015","unstructured":"Corona-Villalobos CP, Halappa VG, Geschwind JF, Bonekamp S, Reyes D, Cosgrove D, et al. Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and Sorafenib. Eur Radiol. 2015;25(2):380\u201390.","journal-title":"Eur Radiol"},{"issue":"3","key":"1688_CR13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00270-009-9750-0","volume":"33","author":"K Malagari","year":"2010","unstructured":"Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and Bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010;33(3):541\u201351.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"1688_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1148\/radiol.10100252","volume":"257","author":"AA Bankier","year":"2010","unstructured":"Bankier AA, Levine D, Halpern EF, Kressel HY. Consensus interpretation in imaging research: is there a better way? Radiology. 2010;257(1):14\u20137.","journal-title":"Radiology"},{"key":"1688_CR15","unstructured":"Gwet KL. Handbook of Inter-Rater reliability: the definitive guide to measuring the extent of agreement among raters: vol 2: analysis of quantitative ratings. Advanced Analytics, LLC; 2021."},{"key":"1688_CR16","unstructured":"Gwet KL. Handbook of Inter-Rater reliability: volume 1: analysis of categorical ratings. Advanced Analytics, LLC; 2021."},{"issue":"1","key":"1688_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41597-023-01928-3","volume":"10","author":"AW Moawad","year":"2023","unstructured":"Moawad AW, Morshid A, Khalaf AM, Elmohr MM, Hazle JD, Fuentes D, et al. Multimodality annotated hepatocellular carcinoma data set including pre- and post-TACE with imaging segmentation. Sci Data. 2023;10(1):33.","journal-title":"Sci Data"},{"issue":"3","key":"1688_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.5009\/gnl16001","volume":"11","author":"SO Jeong","year":"2017","unstructured":"Jeong SO, Kim EB, Jeong SW, Jang JY, Lee SH, Kim SG, et al. Predictive factors for complete response and recurrence after transarterial chemoembolization in hepatocellular carcinoma. Gut Liver. 2017;11(3):409\u201316.","journal-title":"Gut Liver"},{"issue":"2","key":"1688_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1688_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"issue":"2","key":"1688_CR21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15(2):155\u201363.","journal-title":"J Chiropr Med"},{"issue":"6","key":"1688_CR22","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.jhep.2019.03.001","volume":"70","author":"T Meyer","year":"2019","unstructured":"Meyer T, Johnson P. Trial endpoints for systemic therapy in patients with hepatocellular carcinoma. J Hepatol. 2019;70(6):1060\u20131.","journal-title":"J Hepatol"},{"issue":"4","key":"1688_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.jhep.2010.10.004","volume":"54","author":"A Riaz","year":"2011","unstructured":"Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol. 2011;54(4):695\u2013704.","journal-title":"J Hepatol"},{"issue":"11","key":"1688_CR24","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.acra.2018.02.013","volume":"25","author":"MH Choi","year":"2018","unstructured":"Choi MH, Park GE, Oh SN, Park MY, Rha SE, Lee YJ, et al. Reproducibility of mRECIST in measurement and response assessment for hepatocellular carcinoma treated by transarterial chemoembolization. Acad Radiol. 2018;25(11):1363\u201373.","journal-title":"Acad Radiol"},{"issue":"16","key":"1688_CR25","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-21-3135","volume":"28","author":"M Kudo","year":"2022","unstructured":"Kudo M, Montal R, Finn RS, Castet F, Ueshima K, Nishida N, et al. Objective response predicts survival in advanced hepatocellular carcinoma treated with systemic therapies. Clin Cancer Res. 2022;28(16):3443\u201351.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1688_CR26","doi-asserted-by":"publisher","first-page":"e0133488","DOI":"10.1371\/journal.pone.0133488","volume":"10","author":"B Vincenzi","year":"2015","unstructured":"Vincenzi B, Di Maio M, Silletta M, D\u2019Onofrio L, Spoto C, Piccirillo MC, et al. Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with Loco-Regional therapies: A Literature-Based Meta-Analysis. PLoS ONE. 2015;10(7):e0133488.","journal-title":"PLoS ONE"},{"key":"1688_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1471-2288-13-61","volume":"13","author":"N Wongpakaran","year":"2013","unstructured":"Wongpakaran N, Wongpakaran T, Wedding D, Gwet KL. A comparison of Cohen\u2019s kappa and Gwet\u2019s AC1 when calculating inter-rater reliability coefficients: a study conducted with personality disorder samples. BMC Med Res Methodol. 2013;13:61.","journal-title":"BMC Med Res Methodol"},{"issue":"12","key":"1688_CR28","doi-asserted-by":"publisher","first-page":"8903","DOI":"10.1007\/s00330-021-08088-1","volume":"31","author":"I Vicentin","year":"2021","unstructured":"Vicentin I, Mosconi C, Garanzini E, Sposito C, Serenari M, Buscemi V, et al. Inter-center agreement of mRECIST in transplanted patients for hepatocellular carcinoma. Eur Radiol. 2021;31(12):8903\u201312.","journal-title":"Eur Radiol"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01688-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-025-01688-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01688-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T13:30:43Z","timestamp":1746279043000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-025-01688-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1688"],"URL":"https:\/\/doi.org\/10.1186\/s12880-025-01688-z","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,3]]},"assertion":[{"value":"25 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Review board of the University of Texas MD Anderson Cancer Center approved our study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal study"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}